Skip to main content

zolacabtagene autoleucel

Generic: Zolacabtagene Autoleucel

zolacabtagene autoleucel: 5 clinical trials tracked.

zolacabtagene autoleucel evidence translation

What we can confirm

5 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about zolacabtagene autoleucel, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence6 indications · 1 study sponsors
Clinical Trials (5)

A Multicenter, Phase 1, Safety and Tolerability Study of CC-97540 (BMS- 986353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients

NCT07573332·Phase 1
Not yet recruiting

Primary endpoint: To evaluate the safety and tolerability of CC-97540 (BMS-986353) in participants with anti-AQP4 antibody positive NMO as determined by the proportion of patients experiencing DLTs

Interventionalopen5 targetStarted 2026-09Completion 2031-081 site · United StatesUniversity of Texas Southwestern Medical Center

A Phase I/II Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

NCT07388277·Phase 1/Phase 2
Recruiting

Primary endpoint: Safety of CC-97540 in ANCA-Associated Vasculitis

Interventionalopen12 targetStarted 2026-07Completion 2029-121 site · United StatesMarcela V. Maus, M.D.,Ph.D.

A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)

NCT07015983·Phase 2·BMY
Active, not recruiting

Primary endpoint: Proportion of participants achieving drug-free Definition of Remission in Systemic Lupus Erythematosus (DORIS) remission

Interventionalopen89 targetStarted 2025-07Completion 2032-0650 sites · Argentina, Austria, Belgium, Brazil…Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

A Phase 1, Multicenter, Single-arm, Dose-escalation Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants With Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG).

NCT06220201·Phase 1·BMY
Active, not recruiting

Primary endpoint: Number of participants with adverse events (AEs)

Interventionalopen120 targetStarted 2024-03Completion 2027-0734 sites · Belgium, France, Germany, Spain…Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, or Rheumatoid Arthritis (Breakfree-1)

NCT05869955·Phase 1·BMY
Active, not recruiting

Primary endpoint: Number of participants with treatment-emergent adverse events (AEs) in each indication.

Interventionalopen270 targetStarted 2023-09Completion 2028-0846 sites · Belgium, France, Germany, Italy…Juno Therapeutics, Inc., a Bristol-Myers Squibb Company